Avidity Biosciences (RNA) News Today $30.70 +0.35 (+1.16%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Voloridge Investment Management LLC Purchases 134,489 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Voloridge Investment Management LLC grew its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 235.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,550 shares of the biotechnologyMay 28 at 4:31 AM | marketbeat.comWaverly Advisors LLC Takes $259,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Waverly Advisors LLC bought a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 8,914 shares of the biotechnology company's stock, valued at approximatelyMay 28 at 4:31 AM | marketbeat.comSquarepoint Ops LLC Raises Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Squarepoint Ops LLC increased its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 6.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 172,875 shares of the biotechnology company's stock after buying an addiMay 27 at 4:30 AM | marketbeat.comBNP Paribas Financial Markets Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)BNP Paribas Financial Markets acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 21,608 shares of the biotechnology company's stock, valuMay 26 at 3:22 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Neo Ivy Capital ManagementNeo Ivy Capital Management boosted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 479.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,120 shares of the biotechnology company'sMay 25 at 7:09 AM | marketbeat.comTwinbeech Capital LP Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Twinbeech Capital LP purchased a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 19,345 shares of the biotechnology company's stock, valued at approximately $5May 25 at 4:33 AM | marketbeat.comProShare Advisors LLC Raises Position in Avidity Biosciences, Inc. (NASDAQ:RNA)ProShare Advisors LLC lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 35.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,909 shares of the biotechnology company's stoMay 25 at 4:04 AM | marketbeat.comCastleark Management LLC Increases Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Castleark Management LLC increased its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 23.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,620 shares of the biotechnology company's sMay 24, 2025 | marketbeat.comWoodline Partners LP Has $25.18 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Woodline Partners LP boosted its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 27.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 865,820 shares of the biotechnology company's stock after purchasing anMay 23, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.21 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 19.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 144,570 shaMay 22, 2025 | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 21, 2025 | prnewswire.comDeutsche Bank AG Purchases 30,340 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Deutsche Bank AG grew its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 18.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 193,586 shares of the biotechnology company's stock after buying an additional 30May 21, 2025 | marketbeat.comAvidity Biosciences Sees Unusually Large Options Volume (NASDAQ:RNA)May 21, 2025 | americanbankingnews.comRafferty Asset Management LLC Sells 22,381 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Rafferty Asset Management LLC cut its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 11.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,984 shares of the biotecMay 20, 2025 | marketbeat.comMan Group plc Sells 487,710 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Man Group plc lessened its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 53.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 422,421 shares of the biotechnMay 20, 2025 | marketbeat.comBioscience Firms in Southern California Focus on Innovation & CollaborationMay 18, 2025 | latimes.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by RTW Investments LPRTW Investments LP decreased its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,932,870 shares of the biotechnology company's stockMay 18, 2025 | marketbeat.comHC Wainwright Issues Negative Estimate for RNA EarningsAvidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 EPS estimates for Avidity Biosciences in a report released on Monday, May 12th. HC Wainwright analyst A. Ghosh now expects that the biotechnology company will post earnings ofMay 17, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Holdings Decreased by Polar Capital Holdings PlcPolar Capital Holdings Plc lessened its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 17.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,271,891 sMay 17, 2025 | marketbeat.comMPM Bioimpact LLC Has $20.44 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)MPM Bioimpact LLC grew its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 702,981 shares of the biotechnology company's stock after acMay 16, 2025 | marketbeat.comNicholas Investment Partners LP Makes New $2.02 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)Nicholas Investment Partners LP purchased a new position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 69,570 shares of the biotMay 16, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Outlook for RNA EarningsAvidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for Avidity Biosciences in a report released on Monday, May 12th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company will post earnings ofMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Trims Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Orbimed Advisors LLC cut its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,112,886 shares of the biotechnology company's stock after selling 31,919May 15, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Cuts Position in Avidity Biosciences, Inc. (NASDAQ:RNA)D. E. Shaw & Co. Inc. decreased its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 49.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 558,969 shares of the biotechMay 15, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Given New $68.00 Price Target at HC WainwrightHC Wainwright lowered their target price on shares of Avidity Biosciences from $72.00 to $68.00 and set a "buy" rating on the stock in a report on Monday.May 14, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Acquired by Janus Henderson Group PLCJanus Henderson Group PLC boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 44.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,053,010 shares of the biotechnology company's stock aMay 14, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 23,752 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Balyasny Asset Management L.P. reduced its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 14.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 137,057 shares of the biotechnoMay 13, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Northern Trust CorpNorthern Trust Corp raised its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 11.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,079,434 shares of the biotechnology company's stock after purchasing an additional 108,303 shares dMay 13, 2025 | marketbeat.comFORA Capital LLC Invests $546,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)FORA Capital LLC bought a new position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 18,787 shares of the biotechnology company's stock, valued at approximately $5May 12, 2025 | marketbeat.comScotiabank Sticks to Its Buy Rating for Avidity Biosciences (RNA)May 11, 2025 | theglobeandmail.comDriehaus Capital Management LLC Has $35.71 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Driehaus Capital Management LLC increased its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 40.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,228,058 shares of the biotechnologMay 11, 2025 | marketbeat.comAvidity Biosciences First Quarter 2025 Earnings: Misses ExpectationsMay 10, 2025 | finance.yahoo.comBrevan Howard Capital Management LP Buys 26,984 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Brevan Howard Capital Management LP lifted its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 471.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,712 shares of the biotecMay 10, 2025 | marketbeat.comAvidity Biosciences Reports First Quarter 2025 Financial Results and Recent HighlightsMay 9, 2025 | finance.yahoo.comAvidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Avidity Biosciences in a report on Wednesday.May 9, 2025 | marketbeat.comAvidity Biosciences, Inc.: Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent HighlightsMay 9, 2025 | finanznachrichten.deAvidity Biosciences, Inc. (NASDAQ:RNA) Stock Position Decreased by Alyeska Investment Group L.P.Alyeska Investment Group L.P. lowered its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 33.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 50,000 shares of the biotechnology company's stocMay 9, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Buy" from AnalystsAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 12 monMay 9, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Casdin Capital LLCCasdin Capital LLC cut its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 1.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,045,000 shares of the biotechnology company's stock after selling 39,841 shares during thMay 8, 2025 | marketbeat.com3RNA : 12 Analysts Assess Avidity Biosciences: What You Need To KnowMay 7, 2025 | benzinga.comFirst Trust Advisors LP Buys 45,254 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)First Trust Advisors LP lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 110.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 86,395 shares of the biotechnology company's stock after acquiring an additional 45,254 sharesMay 7, 2025 | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferenceMay 6, 2025 | prnewswire.comFreestone Grove Partners LP Takes $523,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Freestone Grove Partners LP acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,971 shares of the biotechnolMay 6, 2025 | marketbeat.comBoxer Capital Management LLC Buys New Shares in Avidity Biosciences, Inc. (NASDAQ:RNA)Boxer Capital Management LLC purchased a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,727,388 shares of the biotMay 4, 2025 | marketbeat.comAvidity Biosciences (RNA) Expected to Announce Quarterly Earnings on ThursdayAvidity Biosciences (NASDAQ:RNA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-avidity-biosciences-inc-stock/)May 3, 2025 | marketbeat.comKathleen P. Gallagher Sells 5,875 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 3, 2025 | insidertrades.com60,641 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Aquatic Capital Management LLCAquatic Capital Management LLC acquired a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 60,641 shares of the biotechnology cMay 1, 2025 | marketbeat.comInvesco Ltd. Lowers Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Invesco Ltd. trimmed its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 69.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,763 shares of the biotechnologyApril 30, 2025 | marketbeat.comTower Research Capital LLC TRC Raises Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Tower Research Capital LLC TRC raised its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2,044.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,029 sharesApril 29, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD grew its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,042,823 shares of theApril 28, 2025 | marketbeat.com Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼1.511.03▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼128▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Blueprint Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNA Stock Free RNA Stock Alerts